Gastroenteritis
INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.
Subtype terms (12)
More specific conditions that are subtypes of Gastroenteritis in the MeSH hierarchy.
- Appendicitis
65 drugs (57 approved, 8 experimental)
- Cholera Morbus
- Colitis
37 drugs (23 approved, 14 experimental)
- Diverticular Diseases
7 drugs (4 approved, 3 experimental)
- Dysentery
15 drugs (7 approved, 8 experimental)
- Enteritis
21 drugs (7 approved, 14 experimental)
- Enterocolitis
13 drugs (7 approved, 6 experimental)
- Esophagitis
39 drugs (23 approved, 16 experimental)
- Gastritis
97 drugs (40 approved, 57 experimental)
- Inflammatory Bowel Diseases
223 drugs (116 approved, 107 experimental)
- Mucositis
134 drugs (76 approved, 58 experimental)
- Proctitis
17 drugs (9 approved, 8 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (15)
Phase 3 trials (25)
- Lirentelimab
- benralizumab
- dupilumab
- echinacea
- lignin hydrolytic
- metamizole
- vitamin c
- papaverine
- propolis
- prulifloxacin
- cellulose
- bifidobacterium infantis
- lactobacillus helveticus
- domperidone
- chickpea
- bivalent oral polio vaccine (bopv), type 1 and type 3
- sodium chloride
- glucose monohydrate
- human rotavirus, live attenuated
- lactobacillus reuteri
- lactobacillus rhamnosus
- cc-93538
- hil-214
- Inactivated polio virus - Enhanced
- mrna-1403
Phase 2 trials (8)
Phase 1 trials (6)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (30)
- Merck
- Sanofi
- Sanofi-Aventis
- Biocodex
- Hamad Medical Corporation
- Telethon Kids Institute
- Centro Pediatrico Albina de Patino
- Cornell University
- Duke University
- Kaohsiung Medical University
- Kocaeli University
- Medical University of Warsaw
- Menzies School of Health Research
- National Yang-Ming University
- Aga Khan University
- Navrongo Health Research Centre, Ghana
- Noguchi Memorial Institute for Medical Research
- Taichung Veterans General Hospital
- University of Calgary
- University of Western Brittany
- International Center for Diarrheal Disease Research
- University of Montreal
- Bill and Melinda Gates Foundation
- Thrasher Research Fund
- Canadian Association of Emergency Physicians
- University Hospital for Infectious Diseases, Croatia
- Centers for Disease Control and Prevention (CDC)
- PATH
- Ankara Yildirim Beyazıt University
- University Clinic for Infectious Diseases "Dr. Fran Mihaljevic"
Organization Involved with Phase 3 Indications (62)
- Optimer Pharmaceuticals
- Allakos, Inc.
- Avva Rus, JSC
- Bharat Biotech International Limited
- BioGaia AB
- GlaxoSmithKline
- Lallemand SAS
- PT Bio Farma
- Serum Institute of India Pvt. Ltd.
- Epicentre
- National Institutes of Health (NIH)
- University of Manitoba
- Brown University
- Gadjah Mada University
- McGill University
- Northwestern University
- Pirogov Russian National Research Medical University
- Sinaloa Pediatric Hospital
- St. Marianna University School of Medicine
- University of Ghana
- University of Michigan
- University of Ottawa
- University of Rochester
- University of Toronto
- University of Alberta
- Wayne State University
- University of Zurich
- Columbia University
- Dalhousie University
- Szpital im. Św. Jadwigi Śląskiej
- +32 more
Organization Involved with Phase 2 Indications (18)
- Regeneron
- Takeda
- AstraZeneca
- Romark
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Parexel
- Shantha Biotechnics Limited
- National Institute of Allergy and Infectious Diseases (NIAID)
- Baylor University
- Cairo University
- Indian Council of Medical Research
- Johns Hopkins University
- Tufts University
- University of Naples Frederico II
- Shin Nippon Biomedical Laboratories
- University of Western Australia
- Nutricia
- PLEURAN s.r.o.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (8)